within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AB09_Dimercaprol;

model Dimercaprol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.7733333333333332e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.00016,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dimercaprol</td></tr><tr><td>ATC code:</td><td>V03AB09</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.16</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.52</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dimercaprol (British anti-Lewisite, BAL) is a chelating agent developed during World War II as an antidote to arsenic-based chemical warfare agents. It is primarily used for the treatment of acute poisoning by heavy metals like arsenic, mercury, gold, and, in combination with other agents, lead. Dimercaprol is not widely used today due to the availability of better-tolerated oral chelators, but can be used in emergencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, following typical intramuscular dosing.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V03AB09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dimercaprol;
